Literature DB >> 6673473

Use of labetalol during anesthesia for pheochromocytoma removal.

M Van Stratum, M Levarlet, J P Lambilliotte, H Lignian, M de Rood.   

Abstract

Labetalol, an alpha and beta adrenergic blocking drug, was used during anesthesia for removal of a very large pheochromocytoma which was predominantly epinephrine secreting. The 70-year-old female patient suffered from angina pectoris and chronic bronchitis. A preoperative treatment including an alpha-adrenolytic drug was administered but beta-adrenergic blockers were avoided because of the risk of cardiac decompensation and bronchoconstriction. During the operation, hypertensive peaks were easily controlled by bolus injections of labetalol 20 mg. The removal of the tumor was followed by a transient moderate hypotension. Heart rate remained stable throughout the operation. No hemodynamic problems occurred during the postoperative period. With regard to this case, a summary of the literature concerning the properties of labetalol is presented.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6673473

Source DB:  PubMed          Journal:  Acta Anaesthesiol Belg        ISSN: 0001-5164


  4 in total

1.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

2.  Pheochromocytoma - update on disease management.

Authors:  Roland Därr; Jacques W M Lenders; Lorenz C Hofbauer; Bernd Naumann; Stefan R Bornstein; Graeme Eisenhofer
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

3.  Perioperative management for resection of a malignant non-chromaffin paraganglioma of the bladder.

Authors:  W M Splinter; B Milne; C Nickel; C Loomis
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

Review 4.  Pheochromocytoma: implications in tumorigenesis and the actual management.

Authors:  U Shah; A Giubellino; K Pacak
Journal:  Minerva Endocrinol       Date:  2012-06       Impact factor: 2.184

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.